<DOC>
	<DOCNO>NCT01095484</DOCNO>
	<brief_summary>The named patient program allow investigator supply rotigotine transdermal system patient document medical necessity receive treatment drug .</brief_summary>
	<brief_title>Named Patient Program With Rotigotine Transdermal System</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject inform give ample time opportunity think her/his participation give her/his write informed consent Subject willing able comply trial requirement Subject either : 1. currently take 3 mg/24 h Rotigotine Idiopathic Restless Legs Syndrome ( RLS ) adult , 6 mg/24 h Rotigotine earlystage Parkinson 's disease , 8 mg/24 h Rotigotine advance stage Parkinson 's disease ( ie , treat concomitant ldopa ) try failed adequate course another dopamine agonist , failure define either suboptimal control symptom development intolerable Adverse Events ( AEs ) ( eg , hallucination ) , 2. take Rotigotine previously demonstrate adequate response follow appropriate course treatment another dopamine agonist ldopa , base investigator 's assessment try failed adequate course another dopamine agonist , 3. complete participation UCB Rotigotine clinical trial SP0934 , SP1055 , RL0003 The investigator attest medical necessity treatment Rotigotine contrast alternate treatment ( eg , dysphagia ) . The investigator receive write approval Sponsor enroll subject Subject pregnant nursing child bear potential ( ) surgically sterile ( ii ) use adequate birth control method ( iii ) sexually abstinent ( iv ) subject least 2 year postmenopausal Subject clinically significant medical condition , psychiatric condition , laboratory abnormality would , judgment investigator , interfere subject 's ability participate trial Subject lifetime history suicide attempt ( include active attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 Columbia Suicide Severity Rating Scale ( C SSRS ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NeuproÂ®</keyword>
</DOC>